Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for FLT3-mutated acute myeloid leukaemia, drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Which FLT3 inhibitor to pair with intensive chemotherapy, and whether one inhibitor suits both ITD and TKD disease.
Whether post-transplant maintenance should be given to everyone or only to patients with detectable FLT3-ITD.
Resistance through FLT3 gatekeeper mutations and through loss of FLT3 dependence.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
Relapse-free survival hazard ratio 0.
Frontline FLT3-ITD AML (QuANTUM-First)
Newly diagnosed FLT3-ITD AML with 7+3, consolidation, and maintenance
A milestone in how this cancer is treated.
OS 31.